You just read:

Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology

News provided by

Takeda Pharmaceutical Company Limited

16 Sep, 2016, 10:48 ET